Impact of Abiraterone Acetate Plus Prednisone or Enzalutamide on Patient-Reported Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Impact of Abiraterone Acetate Plus Prednisone or Enzalutamide on Patient-Reported Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer: Final 12-mo Analysis From the Observational AQUARiUS Study
Eur Urol 2019 Oct 05;[EPub Ahead of Print], A Thiery-Vuillemin, M Hvid Poulsen, E Lagneau, G Ploussard, A Birtle, LM Dourthe, D Beal-Ardisson, E Pintus, R Trepiakas, F Lefresne, M Lukac, S Van Sanden, G Pissart, A ReidFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.